Dr Jill Corre speaks to ecancer about a new classification for identifying HR myeloma based on cytogenetic abnormalities.

Genetic risk factors significantly influence patient stratification and treatment strategies.

Recent advancements emphasise the importance of a genomic consensus that identifies specific mutations affecting treatment decisions.

The complexity of diseases, with various high-risk subgroups, necessitates collaboration among clinicians.

Effective communication and data sharing are vital, while challenges with next-generation sequencing technology and the FISH technique for mutation detection are also addressed.